Bristol-Myers Squibb Bets On New Growth Engines

Bristol-Myers Squibb Company ((BMY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Bristol-Myers Squibb Strikes Optimistic Tone as Growth Engines Offset Patent Pressures

Bristol-Myers Squibb’s latest earnings call struck a decidedly upbeat tone, with management emphasizing strong momentum from its newer medicines, a rich pipeline of upcoming data readouts, and disciplined cost control. While executives openly acknowledged mounting pressures from loss of exclusivity on older drugs and mix-driven margin headwinds, they repeatedly highlighted that high-growth products, a deep bench of late-stage assets, and a more flexible balance sheet are positioning the company for durable growth beyond its legacy portfolio.

Growth Portfolio Outperformance

Bristol-Myers Squibb’s growth portfolio continued to step into the gap left by declining legacy brands. Revenue from this high-growth group climbed 15% year over year in the fourth quarter to $7.4 billion and 17% for the full year, now representing roughly 60% of quarterly sales. Management stressed that this expansion nearly offset an approximate $4 billion annual decline in the legacy portfolio, underscoring the company’s progress in reshaping its revenue base toward newer, more durable assets.

Multiple High-Performing Products

Several individual products stood out as billion-dollar pillars. Immunology and oncology therapies Opdualag, Breyanzi, and cardiology drug Camzyos each surpassed $1 billion in full-year sales, while anemia drug Reblozyl crossed the $2 billion mark. Fourth-quarter growth rates were particularly striking: Breyanzi rose 47%, Reblozyl 21%, Camzyos 57%, Opdivo 7%, and even veteran blood thinner Eliquis delivered 6% growth. This breadth of contribution from both established and newer brands was a central theme of management’s confidence.

Strong Commercial Momentum for New Launches

The company’s latest launches are already showing encouraging traction despite still being early in their lifecycles. Subcutaneous Opdivo (Qvantik/Opdivo SC) generated $133 million in fourth-quarter sales, with practices reacting positively to the more convenient administration format. CoBinfy, launched in a competitive neuroscience space, recorded $51 million in the quarter and is already outpacing uptake trends seen in schizophrenia comparators, surpassing 100,000 total prescriptions since launch. Management framed these early metrics as proof points that commercial execution is resonating with physicians and patients.

Robust Pipeline and Near-Term Catalysts

Executives repeatedly described 2026 as a “data-rich” year, pointing to top-line registrational results expected for roughly six potential new products and more than 30 meaningful launch opportunities by 2030. Near-term catalysts include label expansions for Breyanzi following a recent FDA approval in marginal zone lymphoma, multiple registrational studies for pemigatinib, and the Break Free SSC program for Zolacel. Investors are also watching upcoming oral data for Nablometastat. While management acknowledged the usual execution risk inherent in late-stage trials, the breadth and depth of the pipeline were highlighted as a key driver of future value.

2026 Financial Guidance and EPS Outlook

For 2026, Bristol-Myers Squibb guided to non‑GAAP revenue between $46.0 billion and $47.5 billion and adjusted diluted EPS of $6.05 to $6.35. The outlook assumes continued robust performance from the growth portfolio alongside planned declines in legacy products. Management’s confidence in this range rests on double-digit growth in newer brands, ongoing expense discipline, and the ability of new launches and pipeline approvals to offset erosion from older drugs approaching or past patent expiry.

Progress on Cost Savings and Expense Management

The company is delivering ahead on its multiyear productivity program. Roughly $1 billion of a targeted $2 billion in strategic cost savings has already been realized in 2025, with the remaining ~$1 billion slated for 2026–2027. Full-year operating expenses (excluding in-process R&D) declined to $16.6 billion, down $1.2 billion versus 2024, and 2026 operating expense guidance sits at about $16.3 billion. Management underscored that these savings are being achieved without sacrificing pipeline investment, positioning the company to expand margins over time despite product mix headwinds.

Balance Sheet and Cash Flow Strength

Bristol-Myers Squibb’s financial flexibility has improved materially. As of year-end 2025, the company reported approximately $11 billion in cash and marketable securities and confirmed that it had completed a planned $10 billion debt paydown ahead of schedule. Fourth-quarter operating cash flow came in around $2 billion. This balance sheet strength, combined with steady cash generation, gives management room to invest in R&D, pursue business development, and navigate upcoming patent cliffs without overreliance on additional leverage.

Commercial Positioning and Market Access Wins

On the commercial front, Bristol-Myers Squibb continues to defend and expand share in key markets. Eliquis remains a cornerstone, holding roughly 75% share in U.S. atrial fibrillation and expected to grow 10%–15% in 2026, with the second half outpacing the first. In oncology, Opdualag and Opdivo are gaining share in metastatic melanoma and first-line non-small cell lung cancer, respectively. The company is also pushing hard on subcutaneous Opdivo, targeting a conversion of 30%–40% of the intravenous business by 2028, which could improve patient convenience and support durable oncology revenue.

Legacy Portfolio Declines and LOE Headwinds

The flip side of the growth story is a shrinking legacy portfolio. Full-year revenue from older brands declined by about $4 billion, and the company projects another 12%–16% drop in 2026 as loss-of-exclusivity pressures mount and generics enter more markets. Management framed this decline as expected and manageable, arguing that the growing weight of newer products in the revenue mix is already cushioning the blow and will continue to do so in the years ahead.

Gross Margin Pressure

Gross margin came under pressure in the latest quarter, highlighting a key investor watch point. Fourth-quarter gross margin fell 210 basis points to 71.9%, primarily due to shifts in product mix, including contributions from Eliquis and Revlimid. For 2026, the company guided gross margin in the 69%–70% range, signaling that mix-related headwinds will persist as the portfolio transitions. Management is leaning on cost efficiencies and higher-margin new launches to offset some of this pressure over time.

One-Time Charges and EPS Impact

Earnings were also affected by one-time in-process R&D and licensing charges, which cut EPS by $0.60 in the fourth quarter and $1.40 for the full year. These items contributed to an elevated effective tax rate of 22.1% in Q4 versus 19.9% a year earlier. While these charges weighed on reported results, management framed them as strategic investments in future growth rather than structural drags, and emphasized that core operating performance remained solid.

Eliquis Future Sales Step-Down Risk

Looking beyond 2026, investors will be closely watching the trajectory of Eliquis, one of Bristol-Myers Squibb’s largest contributors. Management anticipates a step-down in Eliquis sales of $1.5 billion to $2.0 billion in 2027 versus 2026, driven by patent expirations and the arrival of generics outside the U.S. The exact timing and severity of the decline remain uncertain, with country-specific litigation outcomes playing a key role. The company is positioning its growing portfolio of newer drugs to fill this expected gap.

Concentration and Early-Stage Sales for New Products

Despite encouraging launch trends, management acknowledged that several new products are still in the early innings, with relatively modest current revenue. CoBinfy’s $51 million and Qvantik’s $133 million in fourth-quarter sales, while promising, underscore the need for sustained uptake, broader physician adoption, and label expansion to achieve true scale. The company is banking on these assets, along with other pipeline candidates, to mature into material contributors as legacy revenues fade.

Regulatory, Clinical, and Competitive Risks

The call also underscored the inherent risks that accompany an innovation-led strategy. Key clinical readouts expected in 2026—including Milvexian in atrial fibrillation, multiple CELMoD programs, and pemigatinib registrational studies—are pivotal but not guaranteed. At the same time, competitive pressures from bispecific antibodies, biosimilars, and rival small molecules could squeeze market share in several franchises. Management acknowledged these challenges but pointed to the company’s diversification across multiple therapeutic areas and mechanisms as a buffer against any single setback.

Forward-Looking Guidance and Outlook

Bristol-Myers Squibb’s 2026 guidance paints a picture of controlled transition. The company expects non‑GAAP revenue of $46.0–$47.5 billion, gross margin of 69%–70%, adjusted diluted EPS of $6.05–$6.35, and total operating expenses of about $16.3 billion, with other income and expense around $700 million and an estimated 18% tax rate. Management expects the growth portfolio—already delivering mid‑teens growth and representing the majority of revenue—to drive performance, while the legacy portfolio falls 12%–16%. Eliquis is forecast to grow 10%–15% in 2026, with stronger trends in the second half, before an expected $1.5–$2.0 billion step-down in 2027. Seasonal destocking is anticipated in the first quarter, but robust cash generation, approximately $11 billion in cash, and a completed $10 billion debt reduction, alongside a $2 billion productivity program, give the company ample room to navigate volatility and invest for the long term.

In sum, Bristol-Myers Squibb’s earnings call presented a story of a big pharma player in the midst of a managed handoff—from aging blockbusters facing patent cliffs to a new wave of oncology, hematology, and cardiovascular assets driving growth. While margin pressures, patent expiries, and clinical risk remain real concerns, management’s tone was confident that strong commercial execution, a crowded pipeline of upcoming catalysts, and a strengthened balance sheet will allow the company to absorb these headwinds and continue delivering for shareholders over the coming years.